| adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma |
NCT06192186: Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma |
|
|
| Recruiting | 4 | 110 | RoW | Adebrelimab combined with SOX regimen, Placebo combined with SOX (S-1/oxaliplatin) regimen | Yang Jianjun, PhD | Locally Advanced Gastric Adenocarcinoma | 12/25 | 12/25 | | |
NCT06417606: Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma |
|
|
| Not yet recruiting | 4 | 20 | RoW | Lenvatinib, Adebrelimab, GEMOX（Gemcitabine and oxaliplatin） | Zhiyong Huang | Intrahepatic Cholangiocarcinoma | 04/25 | 05/25 | | |
| Not yet recruiting | 4 | 30 | | Adbelimab + Apatinib mesylate + albumin bound paclitaxel | He'nan Cancer Hospital; He'nan Cancer Hospital, Self-funded | SLC | | | | |
ChiCTR2300075011: Consolidation therapy of Adebrelimab for stage III unresectable NSCLC after concurrent radiotherapy and chemotherapy (cCRT combined with or without Adebrelimab) |
|
|
| Recruiting | 4 | 120 | | Adebrelimab+pemetrexed/Albumin paclitaxel+ carboplatin/cisplatin，The dose of chest radiation therapy is 60-66Gy/30-33f. Consolidation therapy After four cycles of combined treatment, the patients received a dosing cycle of 1200 mg Q3W of Adebrelimab. Until PD or intolerable toxicity. ;pemetrexed/Albumin paclitaxel+ carboplatin/cisplatin，The dose of chest radiation therapy is 60-66Gy/30-33f. Consolidation therapy After four cycles of combined treatment, the patients received a dosing cycle of 1200 mg Q3W of Adebrelimab. Until PD or intolerable toxicity. | Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital, Self-financing | non-small cell lung cancer | | | | |
ChiCTR2300074932: Adebrelimab as ffrst-line treatment for extensive-stage small-cell lung cancer: A real world study |
|
|
| Recruiting | 4 | 500 | | NA ;NA | Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital, Self-financing | small cell lung cancer | | | | |
ChiCTR2300074591: Prospective study of neoadjuvant adebrelimab combined with chemotherapy in limited-stage small cell lung cancer |
|
|
| Not yet recruiting | 4 | 28 | | adebrelimab + etoposide + carboplatin/cisplatin | Lung Cancer Center, West China Hospital, Sichuan University; Lung Cancer Center, West China Hospital, Sichuan University, Suzhou Shengdiya Biopharmaceutical Co., Ltd. | small cell lung cancer | | | | |
ChiCTR2300077557 :
Adebrelimab in Combination With Carboplatin and Etoposide as Perioperative Treatment in Patients With Resectable Stage IIB-IIIA Small Cell Lung Cancer:A Single Arm, Single Center, Prospective, Exploratory Clinical Study |
|
|
| Recruiting | 4 | 27 | | Neoadjuvant therapy On the first day of each cycle, intravenous drip of adebrelimab was administered, followed by etoposide 100mg/m2 d1, 2, 3, and carboplatin AUC 5 mg/mL · min d1, a total of 3 cycles. After three cycles of combined treatment, surgery is performed after an interval of 4-6 weeks. Adjuvant therapy After the surgery, the subjects received etoposide 100mg/m2 d1, 2, 3, and carboplatin AUC 5 mg/mL · min, d1, 1-3 cycles. The decision on whether to combine synchronous/sequential radiotherapy or maintenance therapy with adebrelimab after the surgery was discussed and determined by MDT. | Shandong First Medical University Affiliated Cancer Hospital |
Small cell lung cancer | | | | |
ChiCTR2300074620: Adebrelimab combined with neoadjuvant chemotherapy for locally advanced cervical cancer: a single-arm, exploratory phase II clinical trial. |
|
|
| Not yet recruiting | 4 | 26 | | Adebrelimab + paclitaxel + cisplatin/carboplatin | The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University, Hengrui Medicine | Cervical cancer | | | | |
